blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP0866656

EP0866656 - USE OF N-SUBSTITUTED PYRIDONES AS TUMOR NECROSIS FACTOR ALPHA INHIBITORS [Right-click to bookmark this link]
Former [1998/40]INHIBITION OF TUMOR NECROSIS FACTOR ALPHA
[2006/46]
StatusNo opposition filed within time limit
Status updated on  29.02.2008
Database last updated on 02.11.2024
Most recent event   Tooltip17.04.2015Change - lapse in a contracting state
Updated state(s): LI		published on 20.05.2015  [2015/21]
Applicant(s)For all designated states
MARGOLIN, Solomon B.
6723 Desco Drive
Dallas, Texas 75225 / US
[1998/40]
Inventor(s)01 / see applicant
...
[1998/40]
Representative(s)Harrison, Ivor Stanley, et al
Withers & Rogers LLP
4 More London Riverside
London
SE1 2AU / GB
[N/P]
Former [1998/40]Harrison, Ivor Stanley, et al
Withers & Rogers 4 Dyer's Buildings Holborn
London EC1N 2JT / GB
Application number, filing date96933808.617.09.1996
[1998/40]
WO1996US14926
Priority number, dateUS19950003955P19.09.1995         Original published format: US 3955 P
[1998/40]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO9710712
Date:27.03.1997
Language:EN
[1997/14]
Type: A1 Application with search report 
No.:EP0866656
Date:30.09.1998
Language:EN
The application published by WIPO in one of the EPO official languages on 27.03.1997 takes the place of the publication of the European patent application.
[1998/40]
Type: B1 Patent specification 
No.:EP0866656
Date:25.04.2007
Language:EN
[2007/17]
Search report(s)International search report - published on:US27.03.1997
(Supplementary) European search report - dispatched on:EP11.04.2001
ClassificationIPC:A61K31/4412, A61P11/00, A61P19/00, A61P31/00, A61P25/00, A61P17/00, A61P43/00
[2006/46]
CPC:
A61K31/444 (EP); A61K31/4412 (EP); A61K31/4418 (EP);
A61K31/4436 (EP); A61K31/4439 (EP); A61K31/4709 (EP);
A61P1/00 (EP); A61P1/16 (EP); A61P1/18 (EP);
A61P11/00 (EP); A61P13/00 (EP); A61P13/12 (EP);
A61P17/00 (EP); A61P17/02 (EP); A61P19/00 (EP);
A61P25/00 (EP); A61P25/28 (EP); A61P31/00 (EP);
A61P37/00 (EP); A61P37/08 (EP); A61P43/00 (EP);
A61P5/00 (EP); A61P9/00 (EP); A61P9/14 (EP);
Y02A50/30 (EP) (-)
Former IPC [1998/40]A01N43/42, A01N43/40, A61K31/47, A61K31/44
Designated contracting statesAT,   BE,   CH,   DE,   DK,   ES,   FI,   FR,   GB,   IT,   LI,   NL,   PT,   SE [1998/40]
TitleGerman:VERWENDUNG VON N-SUBSTITUIERTEN PYRIDONEN ALS TUMORNEKROSE-FAKTOR ALPHA HEMMER[2006/46]
English:USE OF N-SUBSTITUTED PYRIDONES AS TUMOR NECROSIS FACTOR ALPHA INHIBITORS[2006/46]
French:UTILISATION DE PYRIDONES N-SUBSTITUÉES COMME INHIBITEURS DU FACTEUR DE NECROSE TUMORALE ALPHA[2006/46]
Former [1998/40]INHIBIERUNG DES ALPHA TUMORNEKROSE-FAKTORS
Former [1998/40]INHIBITION OF TUMOR NECROSIS FACTOR ALPHA
Former [1998/40]INHIBITION DU FACTEUR $g(a) DE NECROSE TUMORALE
Entry into regional phase14.04.1998National basic fee paid 
14.04.1998Search fee paid 
14.04.1998Designation fee(s) paid 
14.04.1998Examination fee paid 
Examination procedure07.04.1997Request for preliminary examination filed
International Preliminary Examining Authority: US
14.04.1998Examination requested  [1998/40]
12.06.2001Amendment by applicant (claims and/or description)
11.06.2002Despatch of a communication from the examining division (Time limit: M06)
23.12.2002Reply to a communication from the examining division
26.09.2003Despatch of a communication from the examining division (Time limit: M06)
26.03.2004Reply to a communication from the examining division
15.02.2005Despatch of a communication from the examining division (Time limit: M06)
10.08.2005Reply to a communication from the examining division
29.08.2006Despatch of a communication from the examining division (Time limit: M01)
05.10.2006Reply to a communication from the examining division
06.11.2006Communication of intention to grant the patent
09.03.2007Fee for grant paid
09.03.2007Fee for publishing/printing paid
Opposition(s)28.01.2008No opposition filed within time limit [2008/14]
Fees paidRenewal fee
21.09.1998Renewal fee patent year 03
22.12.1999Renewal fee patent year 04
27.07.2000Renewal fee patent year 05
05.09.2001Renewal fee patent year 06
28.08.2002Renewal fee patent year 07
28.08.2003Renewal fee patent year 08
30.08.2004Renewal fee patent year 09
05.09.2005Renewal fee patent year 10
21.09.2006Renewal fee patent year 11
Penalty fee
Additional fee for renewal fee
30.09.199904   M06   Fee paid on   22.12.1999
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT25.04.2007
BE25.04.2007
DK25.04.2007
FI25.04.2007
FR25.04.2007
IT25.04.2007
NL25.04.2007
SE25.07.2007
ES05.08.2007
PT25.09.2007
CH30.09.2007
LI30.09.2007
[2015/21]
Former [2008/52]AT25.04.2007
BE25.04.2007
DK25.04.2007
FI25.04.2007
FR25.04.2007
IT25.04.2007
LI25.04.2007
NL25.04.2007
SE25.07.2007
ES05.08.2007
PT25.09.2007
CH30.09.2007
Former [2008/35]AT25.04.2007
BE25.04.2007
DK25.04.2007
FI25.04.2007
IT25.04.2007
NL25.04.2007
SE25.07.2007
ES05.08.2007
PT25.09.2007
CH30.09.2007
LI30.09.2007
FR21.12.2007
Former [2008/23]AT25.04.2007
BE25.04.2007
DK25.04.2007
FI25.04.2007
IT25.04.2007
LI25.04.2007
NL25.04.2007
SE25.07.2007
ES05.08.2007
PT25.09.2007
FR21.12.2007
Former [2008/12]AT25.04.2007
BE25.04.2007
DK25.04.2007
FI25.04.2007
LI25.04.2007
NL25.04.2007
SE25.07.2007
ES05.08.2007
PT25.09.2007
Former [2008/08]AT25.04.2007
BE25.04.2007
DK25.04.2007
FI25.04.2007
LI25.04.2007
SE25.07.2007
ES05.08.2007
PT25.09.2007
Former [2008/06]AT25.04.2007
BE25.04.2007
FI25.04.2007
LI25.04.2007
SE25.07.2007
ES05.08.2007
PT25.09.2007
Documents cited:Search[A]WO9307141  (SMITHKLINE BEECHAM CORP [US]) [A] 1,2* the whole document *;
 [E]WO9627374  (MARGOLIN SOLOMON B [US]) [E] 1-8 * the whole document *
International search[X]US3839346  (GADEKAR S);
 [Y]US3974281  (GADEKAR SHREEKRISHNA M);
 [Y]US4042699  (GADEKAR SHREEKRISHNA M);
 [X]US5227399  (YOUNG ROBERT N [CA], et al);
 [XP]US5518729  (MARGOLIN SOLOMON B [US]);
 [YP]  - HOTAMISLIGIL G S, ET AL., "IRS-1-MEDIATED INHIBITION OF INSULIN RECEPTOR TYROSINE KINASE ACTIVITY IN TNF-ALPHA-AND OBESITY-INDUCED INSULIN RESISTANCE", Science, American Association for the Advancement of Science, US, US, (19960202), vol. 271, doi:10.1126/science.271.5249.665, ISSN 0036-8075, pages 665 - 667, XP001024187

DOI:   http://dx.doi.org/10.1126/science.271.5249.665
 [YP]  - PROBERT L, ET AL., "DISSECTION OF THE PATHOLOGIES INDUCED BY TRANSMEMBRANE AND WILD-TYPE TUMOR NECROSIS FACTOR IN TRANSGENIC MICE", Journal of Leukocyte Biology, Federation of American Societies for Experimental Biology, US, US, (19960401), vol. 59, ISSN 0741-5400, pages 518 - 525, XP002945312
 [Y]  - BEUTLER B, ET AL., "IDENTITY OF TUMOUR NECROSIS FACTOR AND THE MACROPHAGE-SECRETED FACTOR CACHECTIN", NATURE, Nature Publishing Group, United Kingdom, United Kingdom, (19850801), vol. 316, doi:10.1038/316552a0, ISSN 0028-0836, pages 552 - 554, XP002945319

DOI:   http://dx.doi.org/10.1038/316552a0
 [Y]  - PIQUET P F, ET AL., "REQUIREMENT OF TUMOUR NECROSIS FACTOR FOR DEVELOPMENT OF SILICA-INDUCED PULMONARY FIBROSIS", NATURE, Nature Publishing Group, United Kingdom, United Kingdom, (19900315), vol. 344, doi:10.1038/344245a0, ISSN 0028-0836, pages 245 - 247, XP002945318

DOI:   http://dx.doi.org/10.1038/344245a0
 [Y]  - BONE R C, "THE PATHOGENESIS OF SEPSIS", ANNALS OF INTERNAL MEDICINE, American College of Physicians, NEW YORK, NY; US, NEW YORK, NY; US, (19910101), vol. 115, ISSN 0003-4819, pages 457 - 469, XP002945317
 [Y]  - EVERSON M P, CHANDLER D B, "CHANGES IN DISTRIBUTION, MORPHOLOGY AND TUMOR NECROSIS FACTOR-ALPHASECRETION OF ALVEOLAR MACROPHAGE SUBPOPULATIONS DURING THE DEVELOPMENT OF BLEOMYCIN-INDUCED PULMONARY FIBROSIS", AMERICAN JOURNAL OF PATHOLOGY., Elsevier Inc., US, US, (19920201), vol. 140, no. 02, ISSN 0002-9440, pages 503 - 512, XP002945316
 [Y]  - DUNCAN M R, BERMAN B, "DIFFERENTIAL REGULATION OF COLLAGEN, GLYCOSAMINOGLYCAN, FIBRONECTINAND COLLAGENASE ACTIVITY PRODUCTION IN CULTURED HUMAN ADULT DERMAL FIBROBLASTS BY INTERLEUKIN 1-ALPHA AND BETA AND TUMOR NECROSIS FACTOR-ALPHA AND BETA", Journal of Investigative Dermatology, Nature Publishing Group, US, US, (19890101), vol. 92, doi:10.1111/1523-1747.ep12696891, ISSN 0022-202X, pages 699 - 706, XP002945314

DOI:   http://dx.doi.org/10.1111/1523-1747.ep12696891
 [Y]  - PIGUET P F, ET AL., "TUMOR NECROSIS FACTOR/GACHECTIN PLAYS A KEY ROLE IN BLEOMYCIN-INDUCED PNEUMOPATHY AND FIBROSIS", The Journal of Experimental Medicine, Rockefeller University Press, US, US, (19890901), vol. 170, doi:10.1084/jem.170.3.655, ISSN 0022-1007, pages 655 - 663, XP002945315

DOI:   http://dx.doi.org/10.1084/jem.170.3.655
 [Y]  - ZIEGLER E, "TUMOR NECROSIS FACTOR IN HUMANS", New England Journal of Medicine, Massachusetts Medical Society, US, US, (19880609), vol. 318, no. 23, ISSN 0028-4793, pages 1533 - 1535, XP002945321
 [YP]  - PERALDI P, ET AL., "TUMOR NECROSIS FACTOR (TNF)-ALPHA INHIBITS INSULIN SIGNALING THROUGH STIMULATION OF THE P55 TNF RECEPTOR AND ACTIVATION OF SPHINGOMYELINASE", Journal of Biological Chemistry, American Society for Biochemistry and Molecular Biology, US, US, (19960531), vol. 271, no. 22, doi:10.1074/jbc.271.22.13018, ISSN 0021-9258, pages 13018 - 13022, XP002945320

DOI:   http://dx.doi.org/10.1074/jbc.271.22.13018
 [Y]  - BEUTLER B, "CYTOKINES AND CANCER CACHEXIA", HOSPITAL PRACTICE., NEW YORK, NY., US, US, (19930401), pages 45 - 52, XP002945313
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.